Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Outcomes

Sponsor

Avera McKennan Hospital & University Health Center (Other)

Overall Status

Completed

CT.gov ID

NCT01274065

Collaborator

(none)

Enrollment

Duration (Months)

Study Details

Study Description

Brief Summary

There is no common rule as to how a drug will affect patients. This is due to the effect specific DNA sequences of genes have on drug response, by the effect they have on how medications are metabolized. The primary objective of this research is to optimize medication therapy and to reduce the number of medications used, specifically medications for people with developmental disabilities and co-occuring psychiatric illnesses.

Condition or Disease	Intervention/Treatment	Phase
Developmental Disabilities	Genetic: Genetic analysis

Detailed Description

The primary goal of this study is to develop a process for utilizing pharmacogenomic analysis as a strategy to improve the quality of life, safety, decrease medication burden, and enhance the effectiveness of medications in people with psychiatric illnesses and developmental disabilities. Ultimately, this inter-disciplinary service could be developed into a standard screening and consultation tool for healthcare providers to utilize when determining the most appropriate medication for their patients.

Study Design

Study Type:

Observational

Actual Enrollment :

38 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Subject Outcomes

Study Start Date :

Sep 1, 2009

Actual Primary Completion Date :

Nov 1, 2014

Actual Study Completion Date :

Nov 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Psychiatric illnesses Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.	Genetic: Genetic analysis The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism Other Names: pharmacogenomics

Arm

Intervention/Treatment

Psychiatric illnesses

Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.

Genetic: Genetic analysis

The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism

Other Names:

pharmacogenomics

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

13 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Current resident of the South Dakota Developmental Center (SDDC)
Currently taking a high number of medications per month
Eligibility of the subjects will be determined by the treatment team which consists of 3-4 of the following individuals: treating psychologist, behavior therapist, case manager, supervisors, counselors, dietitians, physician assistants, occupational therapists, and physical therapists